Impact of GLP-1 Receptor Agonists on Major Gastrointestinal Disorders for Type 2 Diabetes Mellitus: A Mixed Treatment Comparison Meta-Analysis

Figure 3

Plots for ranking probability of different dosing of GLP-1 on GI AEs. EX5BID: exenatide 5 μg twice daily; EX10BID: exenatide 10 μg twice daily; EX2QW: exenatide 2 mg once weekly; LIR0.6: liraglutide 0.6 mg once daily; LIR1.2: liraglutide 1.2 mg once daily; LIR1.8: liraglutide 1.8 mg once daily. Ranking: probability of being the worst treatment, of being the second worst, the third worst and so on, among the 8 comparisons. CT: conventional treatment. SUCRA: surface under the cumulative ranking curve. For rankogram, on the horizontal axis are the eight possible ranks and on the vertical axis the probability of a treatment to achieve each rank. For SUCRA plot, on the horizontal axis is the possible rank of each treatment (from the first best rank to worse according to the outcome). On the vertical axis is the cumulative probability for each treatment to be the best option, among the best two options, among the best three options, and so on.

(a) Plots of these rank probabilities (rankograms)

(b) Plots of cumulative ranking probability (SUCRA)